PEMPFIX Trademark

Trademark Overview

On Thursday, June 2, 2016, a trademark application was filed for PEMPFIX with the United States Patent and Trademark Office. The USPTO has given the PEMPFIX trademark a serial number of 79212465. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, October 25, 2024. This trademark is owned by Immungenetics AG. The PEMPFIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseases, cancer, infectious diseases, fungal diseases, diseases caused by parasites, eye diseases, diseases of the central and peripheral nervous systems, cardiovascular diseases, diseases affecting the immune system, genetic diseases, single gene disorders, mouth, teeth, skin, hair and ear diseases, bone and blood diseases as well as reproductive system diseases; pharmaceutical and biochemical pharmaceutical preparations for contraception; biochemical and chemical pharamceuticals preparations for use with inflammatory diseases, in particular for use with chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against inflammatory diseases, in particular for prevention against chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against chronic and auto...
pempfix

General Information

Serial Number79212465
Word MarkPEMPFIX
Filing DateThursday, June 2, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, October 25, 2024
Registration Number5440650
Registration DateTuesday, April 10, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 23, 2018

Trademark Statements

Goods and ServicesPharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseases, cancer, infectious diseases, fungal diseases, diseases caused by parasites, eye diseases, diseases of the central and peripheral nervous systems, cardiovascular diseases, diseases affecting the immune system, genetic diseases, single gene disorders, mouth, teeth, skin, hair and ear diseases, bone and blood diseases as well as reproductive system diseases; pharmaceutical and biochemical pharmaceutical preparations for contraception; biochemical and chemical pharamceuticals preparations for use with inflammatory diseases, in particular for use with chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against inflammatory diseases, in particular for prevention against chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory skin diseases; biochemical and chemical products for prevention against psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for prevention against blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus diseases; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceuticals preparations for prevention against subepidermal bullous autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoide, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory diseases of the central nervous systems, in particular for prevention against multiple sclerosis; biochemical and chemical pharmaceuticals preparations for the treatment of inflammatory diseases, in particular for the treatment of chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory skin diseases, in particular for the treatment of psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for the treatment of blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus diseases; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceutical preparations for the treatment of subepidermal bullae autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoid, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory diseases of the central nervous system, in particular for the treatment of multiple sclerosis; topical and transdermal pharmaceuticals, in particular creams, dispersions, lotions, ointments, fluids, solutions, sprays, plasters, lacquer and filmforming solutions, for the prevention and treatment of skin diseases of the uppermost skin layer or the upper skin layers; surface treatment pharmaceuticals preparations for use as treatments of immune system diseases, inflammatory diseases, skin, hair and ear diseases; oral administration pharmaceuticals preparations, in particular pills, tablets, lozenges, capsules, liquids, solutions, drops, for the prevention and treatment of central nervous system diseases
Translation of Words in MarkThe word(s) "PEMPIX" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, October 25, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovalis Investments S.L.
Party Type31 - New Owner After Registration
Legal Entity Type99 - Other
AddressES
Party NameImmungenetics AG
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
Address18055 Rostock
DE
Party NameImmungenetics AG
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
Address18055 Rostock
DE
Party NameImmungenetics AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
Address18055 Rostock
DE

Trademark Events

Event DateEvent Description
Wednesday, July 19, 2017ASSIGNED TO EXAMINER
Monday, July 31, 2017NON-FINAL ACTION WRITTEN
Thursday, July 13, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, July 19, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 25, 2017APPLICATION FILING RECEIPT MAILED
Wednesday, November 8, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, November 19, 2017ASSIGNED TO LIE
Wednesday, January 3, 2018NOTICE OF PUBLICATION
Wednesday, January 3, 2018NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 3, 2018NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, January 19, 2018NOTIFICATION PROCESSED BY IB
Tuesday, August 1, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, August 1, 2017REFUSAL PROCESSED BY MPU
Tuesday, August 1, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, August 18, 2017REFUSAL PROCESSED BY IB
Monday, November 27, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 27, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 19, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 23, 2018PUBLISHED FOR OPPOSITION
Tuesday, April 10, 2018REGISTERED-PRINCIPAL REGISTER
Monday, July 30, 2018FINAL DISPOSITION PROCESSED
Monday, July 30, 2018FINAL DISPOSITION NOTICE SENT TO IB
Friday, August 24, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, July 26, 2019NEW REPRESENTATIVE AT IB RECEIVED
Wednesday, February 21, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 10, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Monday, April 10, 2023COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, October 25, 2024CANCELLED SECTION 71
Thursday, April 30, 2020CHANGE OF OWNER RECEIVED FROM IB
Friday, July 30, 2021NEW REPRESENTATIVE AT IB RECEIVED

Related Keywords

pempfix diseases inflammatory preparations biochemical pharmaceutical against prevention chronic chemical particular